Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medtronic investigation

This article was originally published in The Gray Sheet

Executive Summary

Department of Justice sends a letter to Medtronic Nov. 16 requesting any information that the firm also is providing to the Securities and Exchange Commission related to SEC's investigation into possible violations of the U.S. Foreign Corrupt Practices Act, the firm notes in its Dec. 4 quarterly SEC filing. The firm says it is cooperating with DoJ and SEC. In September, SEC notified Stryker, Zimmer, Biomet, Smith & Nephew and Medtronic that it is investigating potential corrupt practices related to the companies' sales of devices in an unspecified number of countries including Greece, Poland and Germany (1"The Gray Sheet" Oct. 22, 2007, p. 10)

You may also be interested in...

Foreign Corrupt Practices Act: Device Industry Under Scrutiny

Federal prosecutors have begun targeting medical device companies in Foreign Corrupt Practices Act investigations

Coronavirus Notebook: US FDA's Paper Push, Industry Exes/US Officials Emphasize Their Collaboration

Dispatches from a world turned upside down include FDA expressing confidence in Chinese manufacturers – to make their GDUFA payments; projections of drug shortages for ventilator patients; and the launch of new hydroxychloroquine studies.

Good News For Immunomedics' Triple Negative Breast Cancer Trial

A Phase III trial testing the antibody-drug conjugate sacituzumab govitecan was stopped early for efficacy, boding well for the BLA pending at the US FDA.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts